Philips-Biocartis deal
This article was originally published in The Gray Sheet
Executive Summary
Molecular diagnostics developer Biocartis will acquire Philips' rapid, fully-automated DNA/RNA molecular diagnostic testing platform under an agreement announced Feb. 10. Potential applications include oncology and infectious disease testing. Financial terms of the agreement were not disclosed
You may also be interested in...
Financings In Brief
Biocartis raises $41 million for diagnostics platform development: Swiss biotech firm raises $41 million in a "Series B" private placement to accelerate development of the rapid, automated DNA/RNA molecular diagnostic testing platform that it bought from Philips in February, Biocartis announces April 8 (1"The Gray Sheet" Feb. 15, 2010). Privately-held Biocartis "will use the proceeds ... to accelerate its plans to finalize the development and validation of the first version of its proprietary new platform," the start-up firm explains. Potential applications include oncology and infectious disease testing. New investors contributing to the financing included Johnson & Johnson Development Corp. and Debiopharm Group. Biopharmaceutical firm Debiopharm will collaborate with Biocartis on companion diagnostics linked to therapies developed by Debiopharm under a personalized medicine partnership announced separately on April 8
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.